Compare GSK plc (GSK) vs Nu Holdings Ltd (NU) Price & Performance

GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.

Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.

NU stock trades at $13.86, up 0.14% today, with a bullish technical signal despite recent earnings misses. Revenue grew from $3.0B in 2022 to $10.6B in 2025, with net income turning positive to $2.9B. The company's expansion in Brazil and Mexico, including a pending banking license acquisition (PYMNTS, 2026-07-22), supports growth. Analysts maintain a buy consensus with a $14.98 target, though competition and Latin American market risks persist.

Outlook remains positive due to strong fundamentals and growth trajectory, but investors face risks from rising competition and regional volatility. The upcoming Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) serves as a key catalyst, with expectations of $0.1984 EPS. Institutional activity is mixed, with some trimming stakes while others increase holdings.